These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 11500390)

  • 1. Predominance of serotype-specific mucosal antibody response in Shigella flexneri-infected humans living in an area of endemicity.
    Rasolofo-Razanamparany V; Cassel-Beraud AM; Roux J; Sansonetti PJ; Phalipon A
    Infect Immun; 2001 Sep; 69(9):5230-4. PubMed ID: 11500390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-reactivity of Shigella flexneri serotype 2a O antigen antibodies following immunization or infection.
    Van De Verg LL; Bendiuk NO; Kotloff K; Marsh MM; Ruckert JL; Puryear JL; Taylor DN; Hartman AB
    Vaccine; 1996 Aug; 14(11):1062-8. PubMed ID: 8879103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Presence of specific immunoglobulin A-secreting cells in peripheral blood after natural infection with Shigella sonnei.
    Orr N; Robin G; Lowell G; Cohen D
    J Clin Microbiol; 1992 Aug; 30(8):2165-8. PubMed ID: 1500527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoclonal immunoglobulin A antibody directed against serotype-specific epitope of Shigella flexneri lipopolysaccharide protects against murine experimental shigellosis.
    Phalipon A; Kaufmann M; Michetti P; Cavaillon JM; Huerre M; Sansonetti P; Kraehenbuhl JP
    J Exp Med; 1995 Sep; 182(3):769-78. PubMed ID: 7544397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Shigella lipopolysaccharide antibodies in pediatric populations.
    Passwell JH; Freier S; Shor R; Farzam N; Block C; Lison M; Shiff E; Ashkenazi S
    Pediatr Infect Dis J; 1995 Oct; 14(10):859-65. PubMed ID: 8584312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of antibodies to Shigella lipopolysaccharide in urine after natural Shigella infection or vaccination.
    Cohen D; Orr N; Robin G; Slepon R; Ashkenazi S; Ashkenazi I; Shemer J
    Clin Diagn Lab Immunol; 1996 Jul; 3(4):451-5. PubMed ID: 8807212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunoglobulin subclass distribution and dynamics of Shigella-specific antibody responses in serum and stool samples in shigellosis.
    Islam D; Wretlind B; Ryd M; Lindberg AA; Christensson B
    Infect Immun; 1995 May; 63(5):2054-61. PubMed ID: 7729920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of monoclonal antibodies to type Shigella flexneri in Bangladesh.
    Carlin NI; Rahman M; Sack DA; Zaman A; Kay B; Lindberg AA
    J Clin Microbiol; 1989 Jun; 27(6):1163-6. PubMed ID: 2666435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective study of systemic and mucosal immune responses in dysenteric patients to specific Shigella invasion plasmid antigens and lipopolysaccharides.
    Oberhelman RA; Kopecko DJ; Salazar-Lindo E; Gotuzzo E; Buysse JM; Venkatesan MM; Yi A; Fernandez-Prada C; Guzman M; León-Barúa R
    Infect Immun; 1991 Jul; 59(7):2341-50. PubMed ID: 2050402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative analysis of IgG class and subclass and IgA serum response to Shigella sonnei and Shigella flexneri 2a polysaccharides following vaccination with Shigella conjugate vaccines.
    Robin G; Keisari Y; Slepon R; Ashkenazi S; Cohen D
    Vaccine; 1999 Aug; 17(23-24):3109-15. PubMed ID: 10462247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Shigella-specific IgA in saliva of children with bacillary dysentery.
    Schultsz C; Qadri F; Hossain SA; Ahmed F; Ciznar I
    FEMS Microbiol Immunol; 1992 Jan; 4(2):65-72. PubMed ID: 1547024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specificity of monoclonal antibodies elicited by mucosal infection of BALB/c mice with virulent Shigella flexneri 2a.
    Hartman AB; Van de Verg LL; Mainhart CR; Tall BD; Smith-Gill SJ
    Clin Diagn Lab Immunol; 1996 Sep; 3(5):584-9. PubMed ID: 8877140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Highly homogenous tri-acylated S-LPS acts as a novel clinically applicable vaccine against Shigella flexneri 2a infection.
    Ledov VA; Golovina ME; Markina AA; Knirel YA; L'vov VL; Kovalchuk AL; Aparin PG
    Vaccine; 2019 Feb; 37(8):1062-1072. PubMed ID: 30670300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of an intranasal Shigella flexneri 2a Invaplex 50 vaccine.
    Riddle MS; Kaminski RW; Williams C; Porter C; Baqar S; Kordis A; Gilliland T; Lapa J; Coughlin M; Soltis C; Jones E; Saunders J; Keiser PB; Ranallo RT; Gormley R; Nelson M; Turbyfill KR; Tribble D; Oaks EV
    Vaccine; 2011 Sep; 29(40):7009-19. PubMed ID: 21787825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of prior infection with virulent Shigella flexneri 2a on the resistance of monkeys to subsequent infection with Shigella sonnei.
    Formal SB; Oaks EV; Olsen RE; Wingfield-Eggleston M; Snoy PJ; Cogan JP
    J Infect Dis; 1991 Sep; 164(3):533-7. PubMed ID: 1869840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationalizing the design of a broad coverage Shigella vaccine based on evaluation of immunological cross-reactivity among S. flexneri serotypes.
    Citiulo F; Necchi F; Mancini F; Rossi O; Aruta MG; Gasperini G; Alfini R; Rondini S; Micoli F; Rappuoli R; Saul A; Martin LB
    PLoS Negl Trop Dis; 2021 Oct; 15(10):e0009826. PubMed ID: 34644291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stable Chromosomal Expression of Shigella flexneri 2a and 3a O-Antigens in the Live Salmonella Oral Vaccine Vector Ty21a.
    Dharmasena MN; Osorio M; Takeda K; Stibitz S; Kopecko DJ
    Clin Vaccine Immunol; 2017 Dec; 24(12):. PubMed ID: 29046309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development, Interlaboratory Evaluations, and Application of a Simple, High-Throughput
    Nahm MH; Yu J; Weerts HP; Wenzel H; Tamilselvi CS; Chandrasekaran L; Pasetti MF; Mani S; Kaminski RW
    mSphere; 2018 Jun; 3(3):. PubMed ID: 29898979
    [No Abstract]   [Full Text] [Related]  

  • 19. Characterization and quantitative analysis of serum IgG class and subclass response to Shigella sonnei and Shigella flexneri 2a lipopolysaccharide following natural Shigella infection.
    Robin G; Cohen D; Orr N; Markus I; Slepon R; Ashkenazi S; Keisari Y
    J Infect Dis; 1997 May; 175(5):1128-33. PubMed ID: 9129076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults.
    Fries LF; Montemarano AD; Mallett CP; Taylor DN; Hale TL; Lowell GH
    Infect Immun; 2001 Jul; 69(7):4545-53. PubMed ID: 11401998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.